title: Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.
abstract: A prospective seroepidemiological survey was carried out in Luxembourg in 2000-2001 to determine the antibody status of the Luxembourg population against hepatitis A virus (HAV) and hepatitis B virus (HBV). One of the objectives of this survey was to assess the impact of the hepatitis B vaccination programme, which started in May 1996 and included a catch-up campaign for all adolescents aged 12-15 years. Venous blood from 2679 individuals was screened for the presence of antibodies to HAV antigen and antibodies to hepatitis B surface antigen (anti-HBs) using an enzyme immunoassay. Samples positive for anti-HBs were tested for antibody to hepatitis B core antigen (anti-HBc) using a chemiluminiscent microparticle immunoassay to distinguish between individuals with past exposure to vaccine or natural infection. The estimated age-standardized anti-HAV seroprevalence was 42.0% [95% confidence interval (CI) 39.8-44.1] in the population >4 years of age. Seroprevalence was age-dependent and highest in adult immigrants from Portugal and the former Yugoslavia. The age-standardized prevalence of anti-HBs and anti-HBc was estimated at 19.7% (95% CI 18.1-21.3) and 3.16% (95% CI 2.2-4.1) respectively. Anti-HBs seroprevalence exceeding 50% was found in the cohorts targeted by the routine hepatitis B vaccination programme, which started in 1996. Our study illustrates that most young people in Luxembourg are susceptible to HAV infection and that the hepatitis B vaccination programme is having a substantial impact on population immunity in children and teenagers.
authors.affiliation: Laboratoire National de Santé, LuxembourgCRP-Santé, Luxembourg. joel.mossong@lns.etat.lu
authors.forename: J
authors.initials: J
authors.lastname: Mossong
authors.forename: L
authors.initials: L
authors.lastname: Putz
authors.forename: S
authors.initials: S
authors.lastname: Patiny
authors.forename: F
authors.initials: F
authors.lastname: Schneider
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology* / Q000517:prevention & control; D022362:Hepatitis A Vaccines / Q000008:administration & dosage; D030041:Hepatitis A virus / Q000302:isolation & purification*; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D049449:Luminescence; D008189:Luxembourg / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D016036:Seroepidemiologic Studies
chemical_list: D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines